Taiwan Advance Bio-Pharmaceutical バランスシートの健全性
財務の健全性 基準チェック /26
Taiwan Advance Bio-Pharmaceutical has a total shareholder equity of NT$228.8M and total debt of NT$279.1M, which brings its debt-to-equity ratio to 122%. Its total assets and total liabilities are NT$699.3M and NT$470.5M respectively. Taiwan Advance Bio-Pharmaceutical's EBIT is NT$30.2M making its interest coverage ratio 5. It has cash and short-term investments of NT$138.5M.
主要情報
122.0%
負債資本比率
NT$279.08m
負債
| インタレスト・カバレッジ・レシオ | 5x |
| 現金 | NT$138.51m |
| エクイティ | NT$228.81m |
| 負債合計 | NT$470.50m |
| 総資産 | NT$699.32m |
財務状況分析
短期負債: 4186's short term assets (NT$242.3M) do not cover its short term liabilities (NT$284.7M).
長期負債: 4186's short term assets (NT$242.3M) exceed its long term liabilities (NT$185.8M).
デット・ツー・エクイティの歴史と分析
負債レベル: 4186's net debt to equity ratio (61.4%) is considered high.
負債の削減: 4186's debt to equity ratio has increased from 85.2% to 122% over the past 5 years.
債務返済能力: 4186's debt is not well covered by operating cash flow (13.1%).
インタレストカバレッジ: 4186's interest payments on its debt are well covered by EBIT (5x coverage).